Sep. 8 at 8:11 PM
Roivant Sciences said its experimental drug mosliciguat met the primary endpoints in a Phase 2 trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD). In the 135-patient study, the drug reduced pulmonary vascular pressure and resistance by 56.3% versus placebo after 16 weeks and helped patients walk 35.2 meters farther in a six-minute walking test.
CIO Mayukh Sukhatme said mosliciguat’s long half-life could provide greater benefits with longer treatment, with potential use as a standalone or combination therapy. Roivant believes the drug could help reduce hospitalizations, disease exacerbations and deaths in patients with limited life expectancy.
J.P. Morgan analyst Brian Cheng called Roivant a “preferred pick,” saying the results suggest mosliciguat’s potential may exceed his previous risk-adjusted estimate of
$1.5 billion in peak sales for PH-ILD.
$ROIV